Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 4:11:65-68.
doi: 10.1016/j.ymgmr.2017.02.005. eCollection 2017 Jun.

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina

Gustavo Cabrera  1 , Juan Politei  1 , Norberto Antongiovani  1 , Hernán Amartino  1 ; GADYTEF (Grupo Argentino de Diagnóstico y Tratamiento de la Enfermedad de Fabry)
Affiliations

Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina

Gustavo Cabrera et al. Mol Genet Metab Rep. .

Abstract

Evidence regarding long term effectiveness of enzyme replacement therapy (ERT) in Fabry disease (FD) is needed. The aim of this study was to analyze in a cohort of FD patients in Argentina, the long term effectiveness of ERT on renal, cardiac and cerebrovascular parameters.

Methods: Patients with genetically proven FD were included from GADYTEF (Argentinean group for the treatment of FD) between 2001 and 2014. Renal, cardiac, and cerebral outcomes were prospectively studied in patients treated with ERT. Additionally, the occurrence of major cardiac complications, stroke, end-stage renal disease and death was analyzed during follow up.

Results: During the follow-up 8 major complications occurred in 5 patients (n = 2 deaths, n = 4 cases of end stage renal disease and n = 1 atrial fibrillation), 4 of them males and only 1 female who suffered an atrial fibrillation. Sudden death or stroke did not occur. Four (40%) of 10 males with baseline left ventricular hypertrophy (LVH) reduced left ventricular mass index (LVMI) from 163.1 ± 64.7 to 123.4 ± 49.8 g/m2, 2 stabilized LVMI and 4 increased LVMI from157.9 ± 32.3 to 261.6 ± 48.6 g/m2. Estimated glomerular filtration was stable in 30 patients (17 males and 13 females).

Conclusions: We observed a few major complications during the follow up. Future studies are necessary to show the effectiveness of ERT in affected patients.

Keywords: Effectiveness; Enzyme replacement therapy; Fabry disease.

PubMed Disclaimer

References

    1. Ortiz A., Oliveira J.P., Waldek S., Warnock D.G., Cianciaruso B., Wanner C. Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol. Dial. Transplant. 2008;23:1600–1607. - PubMed
    1. Schiffmann R., Warnock D.G., Banikazemi M., Bultas J., Linthorst G.E., Packman S. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol. Dial. Transplant. 2009;24:2102–2111. - PMC - PubMed
    1. Waldek S., Patel M.R., Banikazemi M., Lemay R., Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet. Med. 2009;11:790–796. - PubMed
    1. Banikazemi M., Bultas J., Waldek S., Wilcox W.R., Whitley C.B., McDonald M. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann. Intern. Med. 2007;146:77–86. - PubMed
    1. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S. Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry's disease. N. Engl. J. Med. 2001;345:9–16. - PubMed

LinkOut - more resources